Dr. J. Joseph Kim

• 
  www.rddirections.com/News/index.cfm?articleid=574187&ca - [Cached Version]
  Published on: 10/1/2008    Last Visited: 10/3/2008  

  "This contract substantiates the NIH's endorsement of VGX's approach to DNA vaccines and their delivery via our proprietary in vivo electroporation technology," added Dr. J. Joseph Kim, President and CEO of VGX.

• 
  www.viralgenomix.com/PR_052208.html - [Cached Version]
  Published on: 5/22/2008    Last Visited: 8/1/2008  

  "Publication of this study stresses the potential of VGX technology to improve human and animal health," stated Dr. J. Joseph Kim, President and Chief Executive Officer.

• 
  www.viralgenomix.com/PR_052808.html - [Cached Version]
  Published on: 5/28/2008    Last Visited: 8/1/2008  

  "We are excited that VGX has been selected to make a number of presentations at the prestigious ASGT meeting," stated Dr. J. Joseph Kim, President and Chief Executive Officer.

• 
  www.advisys.net/boards.html - [Cached Version]
  Published on: 4/3/2008    Last Visited: 4/3/2008  

  J. Joseph Kim, Ph.D. Co-Founder, President and CEO.
  
  A co-founder of VGX Pharmaceuticals, Dr. Kim is a veteran of the biopharmaceutical industry.Prior to VGX, Dr. Kim led efforts in manufacturing and process development of several FDA-approved products and developmental therapeutics at Merck.These products include FDA-approved vaccines for Hepatitis as well as developmental vaccines and therapeutics for HIV/AIDS.Dr. Kim has published over 70 peer-reviewed scientific papers and book chapters, holds numerous patents and sits on several editorial boards and review panels.Dr. Kim has garnered many honors during his career.In 2002, Dr. Kim was named as one of the world's top 100 young innovators by Technology Review magazine.The "TR100", as this group is called, was chosen by a very distinguished Panel of Judges (which includes 2 Nobel Prize Laureates).Also in 2002, Dr. Kim was chosen as one the "40 under 40" by the Philadelphia Business Journal as one of the 40 most dynamic professionals who are under 40 years of age in the region.Dr. Kim was also selected on the list of the "50 Most Influential Men" in the October 2003 and in the October 2006 "Power Issue" of Details Magazine.In 2004, Dr. Kim and VGX Pharmaceuticals were selected as one of 30 Technology Pioneers by the World Economic Forum.Furthermore, Dr. Kim was featured in the "Who's Next 2005" issue of Newsweek International, which included a group of 10 leaders, scientists, and executives at the forefront of change and impact in the world.Most recently in 2006, Dr. Kim has been named a Young Global Leader by the Forum of Young Global Leaders, an affiliate of the World Economic Forum.Dr. Kim was among 175 leading executives, public figures and intellectuals under the age of 40 from 50 countries.Dr. Kim has also been featured in articles in Forbes and the New Yorker and in numerous other Media Outlets.
  
  Dr. Kim was trained in economics, engineering and biological sciences at MIT where he was a U.S. Senate Honors Scholar.He holds a Ph.D. in Biochemical Engineering from the University of Pennsylvania and an MBA in Finance from the Wharton School.

• 
  www.viralgenomix.com/PR_070708_Inovio.html - [Cached Version]
  Published on: 7/7/2008    Last Visited: 8/1/2008  

  J. Joseph Kim, Ph.D., co-founder, president and CEO of VGX Pharmaceuticals, said: "Significant, growing evidence indicates that electroporation has a pivotal role to play in enabling the potency of this promising new generation of vaccines and VGX has already made a strong commitment to this DNA delivery technology.
  ...
  The combined company is expected to be led by Dr. J. Joseph Kim as president, CEO and a director, with Dr. Avtar Dhillon serving as a consultant and a director.

• 
  www.pharmafocusasia.com/news/news_archives.asp?NewsID=4 - [Cached Version]
  Published on: 7/1/2008    Last Visited: 9/5/2008  

  Speaking on this, Dr. J. Joseph Kim, President and Chief Executive Officer, VGX Pharmaceuticals, said, "We are pleased with the FDA's acceptance of our VGX-3100 IND application for treating cervical cancer.

• 
  www.viralgenomix.com/PR_062308.html - [Cached Version]
  Published on: 6/23/2008    Last Visited: 8/1/2008  

  "We are pleased to have access to these additional technologies, which further expand our development pipeline of a new generation of DNA-based therapies and vaccines for use in humans," said Dr. J. Joseph Kim, President and CEO of VGX.

• 
  www.advisys.net/DNAvaccines.html - [Cached Version]
  Published on: 4/3/2008    Last Visited: 4/3/2008  

  Dr. J. Joseph Kim, Cofounder and CEO of VGX has been an expert in DNA vaccines since the mid-1990's.Dr. Kim's extensively published area of research was the improvement of immune responses to DNA vaccines by utilizing various molecular adjuvants.Drs.Kim and Weiner collaborated on over 70 biomedical research publications in major academic journals.

• 
  www.sdbj.com/weekly_article.asp?aID=27311866.9267825.16 - [Cached Version]
  Published on: 7/13/2008    Last Visited: 7/13/2008  

  J. Joseph Kim, co-founder and chief executive officer of VGX, will remain at the helm of the combined company.
  ...
  "VGX has been on an aggressive growth path since its inception," Kim said.

• 
  www.centralbanksavannah.com/portal/story.asp?idstr=1134 - [Cached Version]
  Published on: 1/9/2008    Last Visited: 1/9/2008  

  Dr. J. Joseph Kim, Chairman of VGX Animal Health, and President and CEO of VGX Pharmaceuticals, stated, "The APVMA approval is an important validation of our ability to use cutting edge DNA-based technology to improve the health, welfare and productivity of the world's food and companion animal populations.

Page:  1 2 3 4 5